Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Leucine, Phenylalanine, Lysine hydrochloride, Methionine, Isoleucine, Valine, Histidine, Threonine, Tryptophan, Alanine, Glycine, Arginine, Proline, Tyrosine, Serine

×

Overview

What is Travasol?

TRAVASOL 10% (amino acids) injection is a sterile, nonpyrogenic hypertonic solution of essential and nonessential amino acids supplied in a flexible container as a Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program . TRAVASOL is not for direct intravenous infusion.

The formulas for the individual amino acids found in TRAVASOL are provided in .

TRAVASOL contains no more than 25 µg/L of aluminum.



What does Travasol look like?



What are the available doses of Travasol?

Injection: 10% (0.1 grams/mL): 10 grams of amino acid solution per 100 mL in 500 mL, 1000 mL, and 2000 mL flexible containers.

What should I talk to my health care provider before I take Travasol?

How should I use Travasol?

TRAVASOL is indicated as a source of amino acids for patients requiring parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. TRAVASOL may be used to treat negative nitrogen balance in patients.

TRAVASOL is supplied as a pharmacy bulk package for admixing only and is not for direct intravenous infusion. Prior to administration, TRAVASOL must be transferred to a separate PN container, diluted and used as an admixture with or without dextrose, electrolytes and/or lipid emulsion.


What interacts with Travasol?

Sorry No Records found


What are the warnings of Travasol?

Sorry No Records found


What are the precautions of Travasol?

Sorry No Records found


What are the side effects of Travasol?

Sorry No records found


What should I look out for while using Travasol?

The use of TRAVASOL is contraindicated in:


What might happen if I take too much Travasol?

An increased infusion rate of PN can cause hypervolemia, electrolyte disturbances, acidosis and/or azotemia, hyperglycemia, hyperosmolality .

Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.

Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to respiratory and cardiovascular systems.

For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or .


How should I store and handle Travasol?

Store at 20° to 25°C (68° to 77°F); see USP controlled room temperature. Protect from light. Do not freeze.TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in below.Minimize exposure of TRAVASOL to heat and avoid excessive heat.Protect from freezing.Store TRAVASOL at room temperature (25ºC/77ºF).Do not use if protective overpouch has been previously opened or damaged.For storage of admixed solutions .TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in below.Minimize exposure of TRAVASOL to heat and avoid excessive heat.Protect from freezing.Store TRAVASOL at room temperature (25ºC/77ºF).Do not use if protective overpouch has been previously opened or damaged.For storage of admixed solutions .TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in below.Minimize exposure of TRAVASOL to heat and avoid excessive heat.Protect from freezing.Store TRAVASOL at room temperature (25ºC/77ºF).Do not use if protective overpouch has been previously opened or damaged.For storage of admixed solutions .TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in below.Minimize exposure of TRAVASOL to heat and avoid excessive heat.Protect from freezing.Store TRAVASOL at room temperature (25ºC/77ºF).Do not use if protective overpouch has been previously opened or damaged.For storage of admixed solutions .TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in below.Minimize exposure of TRAVASOL to heat and avoid excessive heat.Protect from freezing.Store TRAVASOL at room temperature (25ºC/77ºF).Do not use if protective overpouch has been previously opened or damaged.For storage of admixed solutions .TRAVASOL 10% (amino acids) injection is available in plastic Pharmacy Bulk Package flexible containers in the following sizes as shown in below.Minimize exposure of TRAVASOL to heat and avoid excessive heat.Protect from freezing.Store TRAVASOL at room temperature (25ºC/77ºF).Do not use if protective overpouch has been previously opened or damaged.For storage of admixed solutions .


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
The use of TRAVASOL is contraindicated in:

No drug interactions have been assessed with Crinone.

Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported in patients receiving PN, including TRAVASOL. In some cases, fatal outcomes due to pulmonary embolism have occurred. TRAVASOL contains no added phosphorus. Patients, especially those with hypophosphatemia, may require the addition of phosphate. To prevent hypocalcemia, calcium supplementation should always accompany phosphate administration. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. Precipitates have been reported even in the absence of phosphate salt in the solution. Precipitation following passage through an in-line filter and suspected in vivo precipitate formation has also been reported. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. In addition to inspection of the solution , the infusion set and catheter should also periodically be checked for precipitates.

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

The following adverse reactions from voluntary reports or clinical studies have been reported with TRAVASOL. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).